Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 4.55B 3.95B 3.67B 3.38B 6.37B 434B 6.49B 43.41B 17B 216B 17.07B 16.7B 725B P/E 2026 *
67.6x
P/E 2027 * 34x
Enterprise Value 3.58B 3.11B 2.88B 2.66B 5.01B 341B 5.1B 34.15B 13.37B 170B 13.43B 13.14B 570B EV / Sales 2026 *
2.88x
EV / Sales 2027 * 2.4x
Free-Float
99.68%
Yield 2026 *
-
Yield 2027 * -
1 day+0.80%
1 week+6.93%
Current month+4.94%
1 month+4.94%
3 months+18.26%
6 months+5.65%
Current year-0.60%
1 week 24.99
Extreme 24.99
26.58
1 month 24.23
Extreme 24.232
26.58
Current year 19.89
Extreme 19.89
27.81
1 year 19.69
Extreme 19.69
28.35
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 19/09/2024
Director of Finance/CFO 52 09/09/2021
Chief Tech/Sci/R&D Officer - 03/08/2025
Director TitleAgeSince
Director/Board Member 68 30/04/2008
Chairman 55 09/06/2016
Director/Board Member 73 24/11/2015
Date Insider Type Main position Quantity % Market Cap.
06/02/26 Fiscal year

General Counsel

32,838 0.0194%
17/11/25 Fiscal year

Controller/Auditor

19,948 0.0118%
17/11/25 Fiscal year

Chief Financial Officer

49,914 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%+6.93%+12.83%-8.57% 4.55B
+0.46%+4.53%+0.14%+13.38% 49.37B
-3.95%+14.70%+24.15%+5.15% 39.14B
+6.22%+1.81%+419.17%+647.45% 40.85B
-1.57%-1.44%+7.38%+43.06% 35.81B
+5.56%+11.70%+11.64%+51.50% 30.5B
-0.39%-0.63% - - 16.55B
-1.13%-4.54%+32.10%+126.95% 16.14B
-7.10%-2.81%-8.80%-34.35% 12.77B
+0.35%+3.67%+2.26%+10.00% 13.71B
Average +0.27%+6.01%+55.65%+94.95% 25.94B
Weighted average by Cap. +1.01%+6.99%+79.03%+132.33%

Financials

2026 *2027 *
Net sales 1.24B 1.08B 1B 923M 1.74B 119B 1.77B 11.85B 4.64B 58.86B 4.66B 4.56B 198B 1.4B 1.22B 1.13B 1.04B 1.96B 134B 2B 13.37B 5.24B 66.41B 5.26B 5.14B 223B
Net income 67.44M 58.58M 54.39M 50.16M 94.49M 6.44B 96.2M 644M 252M 3.2B 253M 248M 10.75B 142M 123M 114M 106M 199M 13.55B 202M 1.35B 531M 6.73B 533M 521M 22.63B
Net Debt -970M -842M -782M -721M -1.36B -92.59B -1.38B -9.26B -3.63B -45.99B -3.64B -3.56B -155B -1.18B -1.03B -954M -880M -1.66B -113B -1.69B -11.3B -4.42B -56.1B -4.44B -4.35B -189B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
30/07/26 US$26.55 +0.80% 1,298,677
29/07/26 US$26.34 +1.27% 1,733,147
28/07/26 US$26.01 +2.44% 940,899
27/07/26 US$25.39 +2.21% 1,399,666
24/07/26 US$24.84 +0.04% 1,046,976
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
26.55USD
Average target price
32.95USD
Spread / Average Target
+24.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock